Furthermore, the nanodrug CYT-6091, which was created by linking human TNF alpha (rhTNF) and polyethylene glycol (PEG) to the surface of GNPs, was tested in a phase I clinical trial on a variety of solid tumors, including colon adenocarcinoma. The gene discussed is TNF; the disease is colon adenocarcinoma.